Malignant melanoma is the most aggressive type of skin cancer with invasive growth patterns. Recent advances in melanoma management have focused on cell growth, proliferation, migration, and survival biomarkers. Numerous FDA-approved molecular-targeted therapies, such as tyrosine kinase inhibitors (TKIs), have been developed targeting genetic biomarkers that play a critical role in tumorigenesis when overexpressed. The use of targeted therapies as an alternative or adjuvant to immunotherapy has revolutionized the management of metastatic melanoma. Although this treatment strategy is more efficacious and less toxic than traditional therapies, targeted therapies are less effective after prolonged treatment due to acquired resistance given the mutations and activation of resistant mechanisms in melanoma tumors. In this sense, identifying novel target therapies and repositioned drugs that could modulate the disease progression, the potential molecular and pharmacological mechanisms of therapies are of utmost interest.
The goal of this Research Topic is to raise a discussion on the advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma aiming for high efficacy and minimum side effects. We hope to receive promising results about new or repositioned drugs and elucidate the mechanisms and molecular targets of such therapies in melanoma management and its metastasis.
Therefore, this Research Topic is open to Scope Review, Systematic Review with or without Meta-Analysis, Mini-Review, Clinical Trial, and Original Research articles focusing on understanding the molecular and pharmacological mechanisms of novel targeted therapies for melanoma. Studies dealing with the identification and molecular signaling of pathways related to melanoma progression, and potential treatments are welcome. Of particular interest, immunological modulation of the tumor microenvironment and its responses to pharmacological intervention as well as the application of nanotechnology to diagnostic, monitoring, and therapeutic purposes are high-priority topics. Studies demonstrating the repositioning of drugs that act on molecular targets of melanoma are also welcome.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Malignant melanoma is the most aggressive type of skin cancer with invasive growth patterns. Recent advances in melanoma management have focused on cell growth, proliferation, migration, and survival biomarkers. Numerous FDA-approved molecular-targeted therapies, such as tyrosine kinase inhibitors (TKIs), have been developed targeting genetic biomarkers that play a critical role in tumorigenesis when overexpressed. The use of targeted therapies as an alternative or adjuvant to immunotherapy has revolutionized the management of metastatic melanoma. Although this treatment strategy is more efficacious and less toxic than traditional therapies, targeted therapies are less effective after prolonged treatment due to acquired resistance given the mutations and activation of resistant mechanisms in melanoma tumors. In this sense, identifying novel target therapies and repositioned drugs that could modulate the disease progression, the potential molecular and pharmacological mechanisms of therapies are of utmost interest.
The goal of this Research Topic is to raise a discussion on the advances in molecular and pharmacological mechanisms of novel targeted therapies for melanoma aiming for high efficacy and minimum side effects. We hope to receive promising results about new or repositioned drugs and elucidate the mechanisms and molecular targets of such therapies in melanoma management and its metastasis.
Therefore, this Research Topic is open to Scope Review, Systematic Review with or without Meta-Analysis, Mini-Review, Clinical Trial, and Original Research articles focusing on understanding the molecular and pharmacological mechanisms of novel targeted therapies for melanoma. Studies dealing with the identification and molecular signaling of pathways related to melanoma progression, and potential treatments are welcome. Of particular interest, immunological modulation of the tumor microenvironment and its responses to pharmacological intervention as well as the application of nanotechnology to diagnostic, monitoring, and therapeutic purposes are high-priority topics. Studies demonstrating the repositioning of drugs that act on molecular targets of melanoma are also welcome.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
